An overview of the determinants of CCR5 and CXCR4 co-receptor function

被引：111

作者：

Dragic, T ^{[1
]}

机构：

[1] Yeshiva Univ Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10461 USA

来源：

JOURNAL OF GENERAL VIROLOGY | 2001年 / 82卷

关键词：

D O I：

10.1099/0022-1317-82-8-1807

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

[No abstract available]

引用

页码：1807 / 1814

页数：8

共 109 条

[1] HIV-1 coreceptor activity of CCR5 and its inhibition by chemokines: Independence from G protein signaling and importance of coreceptor downmodulation [J].

Alkhatib, G ;

Locati, M ;

Kennedy, PE ;

Murphy, PM ;

Berger, EA .

VIROLOGY, 1997, 234 (02) :340-348

[2] CC chemokine receptor 5-mediated signaling and HIV-1 co-receptor activity share common structural determinants - Critical residues in the third extracellular loop support HIV-1 fusion [J].

Alkhatib, G ;

Ahuja, SS ;

Light, D ;

Mummidi, S ;

Berger, EA ;

Ahuja, SK .

JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (32) :19771-19776

[3] HIV coreceptor downregulation as antiviral principle: SDF-1 alpha-dependent internalization of the chemokine receptor CXCR4 contributes to inhibition of HIV replication [J].

Amara, A ;

LeGall, S ;

Schwartz, O ;

Salamero, J ;

Montes, M ;

Loetscher, P ;

Baggiolini, M ;

Virelizier, JL ;

ArenzanaSeisdedos, F .

JOURNAL OF EXPERIMENTAL MEDICINE, 1997, 186 (01) :139-146

[4] T134, a small-molecule CXCR4 inhibitor, has no cross-drug resistance with AMD3100, a CXCR4 antagonist with a different structure [J].

Arakaki, R ;

Tamamura, H ;

Premanathan, M ;

Kanbara, K ;

Ramanan, S ;

Mochizuki, K ;

Baba, M ;

Fujii, N ;

Nakashima, H .

JOURNAL OF VIROLOGY, 1999, 73 (02) :1719-1723

[5] Multiple extracellular elements of CCR5 and HIV-1 entry: Dissociation from response to chemokines [J].

Atchison, RE ;

Gosling, J ;

Monteclaro, FS ;

Franci, C ;

Digilio, L ;

Charo, IF ;

Goldsmith, MA .

SCIENCE, 1996, 274 (5294) :1924-1926

[6] A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity [J].

Baba, M ;

Nishimura, O ;

Kanzaki, N ;

Okamoto, M ;

Sawada, H ;

Iizawa, Y ;

Shiraishi, M ;

Aramaki, Y ;

Okonogi, K ;

Ogawa, Y ;

Meguro, K ;

Fujino, M .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (10) :5698-5703

[7] Human immunodeficiency virus (HIV) envelope binds to CXCR4 independently of CD4, and binding can be enhanced by interaction with soluble CD4 or by HIV envelope deglycosylation [J].

Bandres, JC ;

Wang, QF ;

O'Leary, J ;

Baleaux, F ;

Amara, A ;

Hoxie, JA ;

Zolla-Pazner, S ;

Gorny, MK .

JOURNAL OF VIROLOGY, 1998, 72 (03) :2500-2504

[8] Patterns of CCR5, CXCR4, and CCR3 usage by envelope glycoproteins from human immunodeficiency virus type 1 primary isolates [J].

Bazan, HA ;

Alkhatib, G ;

Broder, CC ;

Berger, EA .

JOURNAL OF VIROLOGY, 1998, 72 (05) :4485-4491

[9] The CCR5 deletion mutation fails to protect against multiple sclerosis [J].

Bennetts, BH ;

Teutsch, SM ;

Buhler, MM ;

Heard, RNS ;

Stewart, GJ .

HUMAN IMMUNOLOGY, 1997, 58 (01) :52-59

[10] A new classification for HIV-1 [J].

Berger, EA ;

Doms, RW ;

Fenyö, EM ;

Korber, BTM ;

Littman, DR ;

Moore, JP ;

Sattentau, QJ ;

Schuitemaker, H ;

Sodroski, J ;

Weiss, RA .

NATURE, 1998, 391 (6664) :240-240

← 1 2 3 4 5 6 7 8 9 10 →